{"drugs":["Lipegfilgrastim","Lonquex"],"mono":{"0":{"id":"930803-s-0","title":"Generic Names","mono":"Lipegfilgrastim"},"1":{"id":"930803-s-1","title":"Dosing and Indications","sub":[{"id":"930803-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Febrile neutropenia, In nonmyeloid malignancies after myelosuppressive chemotherapy; Prophylaxis:<\/b> 6 mg subQ for each chemotherapy cycle administered approximately 24 hours after cytotoxic chemotherapy<\/li><li><b>Neutropenia (Severe), In nonmyeloid malignancies after myelosuppressive chemotherapy; Prophylaxis:<\/b> 6 mg subQ for each chemotherapy cycle administered approximately 24 hours after cytotoxic chemotherapy<\/li><\/ul>"},{"id":"930803-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy of lipegfilgrastim not established in pediatric patients up to 17 years of age "},{"id":"930803-s-1-6","title":"Dose Adjustments","mono":"<b>geriatric:<\/b> no dosage adjustment needed "},{"id":"930803-s-1-7","title":"Indications","mono":"<b>Non-FDA Labeled Indications<\/b><ul><li>Febrile neutropenia, In nonmyeloid malignancies after myelosuppressive chemotherapy; Prophylaxis<\/li><li>Neutropenia (Severe), In nonmyeloid malignancies after myelosuppressive chemotherapy; Prophylaxis<\/li><\/ul>"}]},"3":{"id":"930803-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930803-s-3-9","title":"Contraindications","mono":"Hypersensitivity to lipegfilgrastim or any component of the product <br\/>"},{"id":"930803-s-3-10","title":"Precautions","mono":"<ul><li>Endocrine and Metabolic:<\/li><li>-- Patients with hereditary fructose intolerance; not recommended<\/li><li>-- Hypokalemia may occur; monitoring recommended for patients at increased risk<\/li><li>Hematologic:<\/li><li>-- Anemia may occur; monitoring recommended<\/li><li>-- Anti-lipegfilgrastim antibodies may form and lead to adverse events or loss of efficacy<\/li><li>-- Capillary leak syndrome has been reported<\/li><li>-- Leukocytosis may occur; monitoring recommended and discontinuation may be necessary<\/li><li>-- Patients with chronic or secondary acute myeloid leukemia; not recommended<\/li><li>-- Patients with myelodysplastic syndromes; not recommended<\/li><li>-- Reversible thrombocytopenia may occur; monitoring recommended<\/li><li>-- Sickle cell crisis has been reported in patients with sickle cell anemia; monitoring recommended<\/li><li>-- Splenic rupture (including fatal cases) has been reported; monitoring recommended<\/li><li>-- Splenomegaly has been reported; monitoring recommended<\/li><li>Immunologic:<\/li><li>-- Hypersensitivity to granulocyte colony stimulating factor or derivatives; risk of cross-sensitivity; not recommended<\/li><li>Respiratory:<\/li><li>-- Pulmonary adverse reactions (eg, interstitial pneumonia, acute respiratory distress syndrome) have been reported; discontinuation may be necessary<\/li><li>Other:<\/li><li>-- Patients on cytotoxic chemotherapy; not recommended within 24 hours of administration or to increase chemotherapy dose beyond established regimens<\/li><\/ul>"},{"id":"930803-s-3-11","title":"Pregnancy Category","mono":"Fetal risk cannot be ruled out. (TH)<br\/>"},{"id":"930803-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"930803-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Chest pain (1% to less than 10%)<\/li><li><b>Endocrine metabolic:<\/b>Hypokalemia (1% to less than 10%)<\/li><li><b>Musculoskeletal:<\/b>Musculoskeletal pain (10% or greater)<\/li><li><b>Neurologic:<\/b>Headache (1% to less than 10%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Hematologic:<\/b>Capillary leak syndrome, Rupture of spleen, Sickle cell anemia with crisis, Splenomegaly, Thrombocytopenia (1% to less than 10%)<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction (0.1% to less than 1%)<\/li><\/ul>"},"6":{"id":"930803-s-6","title":"Drug Name Info","sub":{"0":{"id":"930803-s-6-17","title":"US Trade Names","mono":"Lonquex<br\/>"},"2":{"id":"930803-s-6-19","title":"Class","mono":"<ul><li>Colony Stimulating Factor<\/li><li>Hematopoietic<\/li><\/ul>"},"3":{"id":"930803-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"930803-s-7","title":"Mechanism Of Action","mono":"Lipegfilgrastim is a recombinant human granulocyte-colony stimulating factor consisting of filgrastim conjugated with a polyethylene glycol molecule joined via a carbohydrate linker allowing it have sustained duration as a stimulator of the proliferation of hematopoietic progenitor cells, other single lineage and multilineage progenitors, and pluripotent hematopoietic stem cells; a stimulator of differentiation into mature cells; and their release into peripheral blood.<br\/>"},"8":{"id":"930803-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"930803-s-8-23","title":"Absorption","mono":"Tmax, subQ: 8 to 48 hours (depending on chemotherapy and cycle) <br\/>"},"2":{"id":"930803-s-8-25","title":"Metabolism","mono":"Intra- and extracellular degradation via proteolytic enzymes <br\/>"},"4":{"id":"930803-s-8-27","title":"Elimination Half Life","mono":"28 to 42 hours (depending on chemotherapy and cycle) <br\/>"}}},"9":{"id":"930803-s-9","title":"Administration","mono":"<b>Subcutaneous<\/b><br\/><ul><li>remove the prefilled syringe from the refrigerator (must be used within 3 days of removal) and allow solution to reach a comfortable temperature (15 to 25 degrees C) before injection<\/li><li>avoid vigorously shaking<\/li><li>inject subQ into the abdomen, upper arm, or thigh<\/li><li>prefilled syringes are for single use only; discard any unused drug<\/li><\/ul>"},"10":{"id":"930803-s-10","title":"Monitoring","mono":"<ul><li>improvement in absolute neutrophil count or reduced neutrophil recovery time is indicative of efficacy<\/li><li>decreased incidence and duration of neutropenia-related sequelae (eg, fever, infections) are indicative of efficacy<\/li><li>anti-drug antibodies, in patients who fail to respond to treatment<\/li><li>platelet count, hematocrit, and WBC count; regularly during therapy<\/li><li>appropriate laboratory tests, in patients with sickle cell anemia<\/li><li>serum potassium levels, in patients at risk for hypokalemia due to underlying disease or concomitant medications<\/li><li>spleen size<\/li><li>signs and symptoms of sickle cell crisis, including splenic enlargement and vasoocclusive crisis, in patients with sickle cell anemia<\/li><\/ul>"},"13":{"id":"930803-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to report symptoms of interstitial pneumonia or acute respiratory distress syndrome.<\/li><li>Counsel patient to report symptoms of anemia or thrombocytopenia.<\/li><li>Side effects may include musculoskeletal pain (bone, joint, or muscle), chest pain, headaches, rash, or skin redness.<\/li><li>Instruct patient to report symptoms of splenic rupture.<\/li><li>Teach patient proper technique and placement of injections (abdomen, upper arm, or thigh).<\/li><\/ul>"}}}